VA
VTGN icon

Verdad Advisers’s VistaGen Therapeutics VTGN Stock Holding History

Verdad Advisers’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$66.3K Buy
293,343
+108,405
+59% +$65.4K 0.06% 197
2026
Q1 		$106K Buy
+184,938
New +$112K 0.12% 154

Other funds holding VTGN

CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
LM
Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Verdad Advisers's VTGN Position: Q2 2026 in Review

Verdad Advisers increased its VistaGen Therapeutics (VTGN) stake by 59% in Q2 2026, buying an estimated $65.4K and bringing the position to 293,343 shares worth $66.3K. The position accounts for 0.06% of the portfolio, ranked #197.

Verdad Advisers first reported a position in VTGN in Q1 2026 and has held it in 2 quarters since. The position peaked at $106K in Q1 2026. 49 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • Verdad Advisers held 293,343 shares of VistaGen Therapeutics worth $66.3K as of Q2 2026.
  • Verdad Advisers bought 108,405 VistaGen Therapeutics shares in Q2 2026, an estimated $65.4K.
  • VistaGen Therapeutics made up 0.06% of Verdad Advisers's portfolio in Q2 2026, its #197 holding.
  • Verdad Advisers first reported a position in VistaGen Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Verdad Advisers's VistaGen Therapeutics position peaked at $106K in Q1 2026.
  • 49 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.